CoChat

Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo

Open access
Violet, Marie, Chauderlier, Alban, Delattre, Lucie, Tardivel, Meryem, Chouala, Meliza Sendid, Sultan, Audrey, Marciniak, Elodie, Humez, Sandrine, Binder, Lester, Kayed, Rakez, Lefebvre, Bruno, Bonnefoy, Eliette, Buée, Luc, Galas, Marie-Christine · 2015 · Neurobiology of Disease
Cited by 66

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

The accumulation of DNA and RNA oxidative damage is observed in cortical and hippocampal neurons from Alzheimer's disease (AD) brains at early stages of pathology. We recently reported that Tau is a key nuclear player in the protection of neuronal nucleic acid integrity in vivo under physiological conditions and hyperthermia, a strong inducer of oxidative stress. In a mouse model of tauopathy (THY-Tau22), we demonstrate that hyperthermia selectively induces nucleic acid oxidative damage and nucleic acid strand breaks in the nucleus and cytoplasm of hippocampal neurons that display early Tau phosphorylation but no Tau fibrils. Nucleic acid-damaged neurons were exclusively immunoreactive for prefibrillar Tau oligomers. A similar association between prefibrillar Tau oligomers and nucleic acid oxidative damage was observed in AD brains. Pretreatment with Methylene Blue (MB), a Tau aggregation inhibitor and a redox cycler, reduced hyperthermia-induced Tau oligomerization as well as nucleic acid damage. This study clearly highlights the existence of an early and critical time frame for hyperthermia-induced Tau oligomerization, which most likely occurs through increased oxidative stress, and nucleic acid vulnerability during the progression of Tau pathology. These results suggest that at early stages of AD, Tau oligomerization triggers the loss of the nucleic acid protective function of monomeric Tau. This study highlights the existence of a short therapeutic window in which to prevent the formation of pathological forms of Tau and their harmful consequences on nucleic acid integrity during the progression of Tau pathology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2015.09.003

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 35

  1. Akoury, 2013, Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation, Angew. Chem. Int. Ed. Engl., 52, 3511, 10.1002/anie.201208290 · DOI · Paper page
  2. Baddeley, 2015, Complex disposition of methylthioninium redox forms determines efficacy in Tau aggregation inhibitor therapy for Alzheimer's disease, J. Pharmacol. Exp. Ther., 352, 110, 10.1124/jpet.114.219352 · DOI
  3. Borgesius, 2011, Accelerated age-related cognitive decline and neurodegeneration, caused by deficient DNA repair, J. Neurosci., 31, 12543, 10.1523/JNEUROSCI.1589-11.2011 · DOI · Paper page
  4. Bradley-Whitman, 2014, Nucleic acid oxidation: an early feature of Alzheimer's disease, J. Neurochem., 128, 294, 10.1111/jnc.12444 · DOI · Paper page
  5. Camero, 2013, Tau protein provides DNA with thermodynamic and structural features which are similar to those found in histone–DNA complex, J. Alzheimers Dis., 39, 649, 10.3233/JAD-131415 · DOI · Paper page
  6. Cooper-Knock, 2012, Gene expression profiling in human neurodegenerative disease, Nat. Rev. Neurol., 8, 518, 10.1038/nrneurol.2012.156 · DOI · Paper page
  7. Deiana, 2009, Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine, Psychopharmacology, 202, 53, 10.1007/s00213-008-1394-2 · DOI
  8. Fabiszewski, 1990, Effect of antibiotic treatment on outcome of fevers in institutionalized Alzheimer patients, JAMA, 263, 3168, 10.1001/jama.1990.03440230064034 · DOI · Paper page
  9. Gerson, 2014, Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species, ACS Chem. Neurosci., 5, 752, 10.1021/cn500143n · DOI · Paper page
  10. Guerrero-Muñoz, 2014, Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins, Biochem. Pharmacol., 88, 468, 10.1016/j.bcp.2013.12.023 · DOI
  11. Hawkins, 2013, Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: possible link between TBI and sporadic tauopathies, J. Biol. Chem., 288, 17042, 10.1074/jbc.M113.472746 · DOI · Paper page
  12. Hikosou, 2007, Effect of DNA on filament formation of tau microtubule-binding domain: structural dependence of DNA, Chem. Pharm. Bull., 55, 1030, 10.1248/cpb.55.1030 · DOI
  13. Hosokawa, 2012, Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice, PLoS One, 7, 10.1371/journal.pone.0052389 · DOI · Paper page
  14. Jiang, 2013, Hyperthermia impaired human visual short-term memory: an fMRI study, Int. J. Hyperth., 29, 219, 10.3109/02656736.2013.786141 · DOI
  15. Lu, 2013, Hyperphosphorylation results in tau dysfunction in DNA folding and protection, J. Alzheimers Dis., 37, 551, 10.3233/JAD-130602 · DOI · Paper page
  16. Moreira, 2008, Nucleic acid oxidation in Alzheimer disease, Free Radic. Biol. Med., 44, 1493, 10.1016/j.freeradbiomed.2008.01.002 · DOI · Paper page
  17. Mufson, 2013, Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer's Disease, Neurodegener. Dis., 13, 151, 10.1159/000353687 · DOI · Paper page
  18. Nunomura, 2012, The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons, J. Neuropathol. Exp. Neurol., 71, 233, 10.1097/NEN.0b013e318248e614 · DOI · Paper page
  19. O'Leary, 2010, Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden, Mol. Neurodegener., 5, 45, 10.1186/1750-1326-5-45 · DOI · Paper page
  20. Patterson, 2011, Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease, J. Biol. Chem., 286, 23063, 10.1074/jbc.M111.237974 · DOI · Paper page
  21. Racinais, 2008, Hyperthermia impairs short-term memory and peripheral motor drive transmission, J. Physiol., 586, 4751, 10.1113/jphysiol.2008.157420 · DOI · Paper page
  22. Reynolds, 2005, Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer's disease, Biochemistry, 44, 1690, 10.1021/bi047982v · DOI · Paper page
  23. Rojas, 2012, Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue, Prog. Neurobiol., 96, 32, 10.1016/j.pneurobio.2011.10.007 · DOI · Paper page
  24. Schindowski, 2006, Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits, Am. J. Pathol., 169, 599, 10.2353/ajpath.2006.060002 · DOI · Paper page
  25. Spires-Jones, 2014, Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy, Neurosci. Lett., 562, 63, 10.1016/j.neulet.2014.01.013 · DOI · Paper page
  26. Stack, 2014, Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity, Hum. Mol. Genet., 23, 3716, 10.1093/hmg/ddu080 · DOI · Paper page
  27. Sutherland, 2013, Oxidative stress in Alzheimer's disease: primary villain or physiological by-product?, Redox Rep., 18, 134, 10.1179/1351000213Y.0000000052 · DOI · Paper page
  28. Tai, 2012, The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin–proteasome system, Am. J. Pathol., 181, 1426, 10.1016/j.ajpath.2012.06.033 · DOI · Paper page
  29. Takeda, 2004, Heme catabolism and heme oxygenase in neurodegenerative disease, Antioxid. Redox Signal., 6, 888
  30. Tepper, 2014, Oligomer formation of tau hyperphosphorylated in cells, J. Biol. Chem., 289, 34389, 10.1074/jbc.M114.611368 · DOI · Paper page
  31. Van der Jeugd, 2013, Progressive age-related cognitive decline in tau mice, J. Alzheimers Dis., 37, 777, 10.3233/JAD-130110 · DOI · Paper page
  32. Vanhelmont, 2010, Serine-409 phosphorylation and oxidative damage define aggregation of human protein tau in yeast, FEMS Yeast Res., 10, 992, 10.1111/j.1567-1364.2010.00662.x · DOI
  33. Ward, 2013, TOC1: characterization of a selective oligomeric tau antibody, J. Alzheimers Dis., 37, 593, 10.3233/JAD-131235 · DOI · Paper page
  34. Zekanowski, 2009, Aneuploidy, chromosomal missegregation, and cell cycle reentry in Alzheimer's disease, Acta Neurobiol. Exp. (Wars), 69, 232, 10.55782/ane-2009-1748 · DOI · Paper page
  35. Zheng-Fischhöfer, 1998, Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation, Eur. J. Biochem., 252, 542, 10.1046/j.1432-1327.1998.2520542.x · DOI · Paper page

Cited by

Metadata

Authors
Violet, M., Chauderlier, A., Delattre, L., Tardivel, M., Chouala, M. S., Sultan, A., Marciniak, E., Humez, S., Binder, L., Kayed, R., Lefebvre, B., Bonnefoy, E., Buée, L., & Galas, M.-C.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2015-10
Volume
82
Pages
540-551
ISSN
0969-9961 (ISSN-L)
OpenAlex
W2214399926
Cited by
66
References
18
FWCI
5.38
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Agence Nationale de la Recherche
  • LabEx
  • DISTALZ
  • INSERM
  • LMCU
  • Région Nord/Pas-de-Calais
  • FEDER

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.